Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling

Shares of Phio Pharmaceuticals Corp jumped 9.8% to $1.23 ahead of the bell Wednesday, buoyed by new safety and response data for its main skin-cancer program. On Tuesday, the stock settled at $1.12, up 24.4%.

11 February 2026

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals, Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com.

3 November 2025